{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:54:57Z","timestamp":1792173297082,"version":"4.4.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"National Science Centre, Poland","doi-asserted-by":"publisher","award":["2014\/13\/D\/NZ3\/02825"],"award-info":[{"award-number":["2014\/13\/D\/NZ3\/02825"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ejps.2018.08.019","type":"journal-article","created":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T22:32:40Z","timestamp":1534285960000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Biotinylated PAMAM G3 dendrimer conjugated with celecoxib and\/or Fmoc-l-Leucine and its cytotoxicity for normal and cancer human cell lines"],"prefix":"10.1016","volume":"124","author":[{"given":"\u0141ukasz","family":"Uram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Filipowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Misiorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Pie\u0144kowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Markowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"Wa\u0142ajtys-Rode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanis\u0142aw","family":"Wo\u0142owiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2018.08.019_bb0005","first-page":"1109","article-title":"Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma","volume":"20","author":"Badawi","year":"2002","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejps.2018.08.019_bb0010","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.bbamcr.2009.05.006","article-title":"Cyclooxygenase-2 functionally inactivates p53 through a physical interaction with p53","volume":"1793","author":"Choi","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejps.2018.08.019_bb0015","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1476-4598-7-38","article-title":"COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro","volume":"7","author":"Chuang","year":"2008","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejps.2018.08.019_bb0020","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/carcin\/bgh076","article-title":"Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin","volume":"25","author":"Chun","year":"2004","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ejps.2018.08.019_bb0025","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1021\/bm301719b","article-title":"Paclitaxel-conjugated PAMAM dendrimers adversely affect microtubule structure through two independent modes of action","volume":"14","author":"Cline","year":"2013","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ejps.2018.08.019_bb0030","doi-asserted-by":"crossref","first-page":"8213","DOI":"10.1158\/1078-0432.CCR-05-1044","article-title":"In vitro and In vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells","volume":"11","author":"Cui","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2018.08.019_bb0035","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S1470-2045(01)00488-0","article-title":"Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer","volume":"2","author":"Dannenberg","year":"2001","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejps.2018.08.019_bb0040","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/09205063.2015.1133155","article-title":"Denrimer-mediated approaches for the treatment of brain tumor","volume":"27","author":"Dwivedi","year":"2016","journal-title":"J. Biomater. Sci. Polym. Ed."},{"key":"10.1016\/j.ejps.2018.08.019_bb0045","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1158\/0008-5472.CAN-06-3952","article-title":"P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines","volume":"67","author":"Fantappi\u00e8","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2018.08.019_bb0050","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1152\/ajpcell.2001.281.1.C188","article-title":"COX-2 expression and cell cycle progression in human fibroblasts","volume":"281","author":"Gilroy","year":"2001","journal-title":"Am. J. Phys. Cell Phys."},{"key":"10.1016\/j.ejps.2018.08.019_bb0055","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/carcin\/bgp014","article-title":"The COX-2\/PGE 2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment","volume":"30","author":"Greenhough","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ejps.2018.08.019_bb0060","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4331\/wjbc.v1.i3.31","article-title":"Anticancer actions of PPAR\u03b3 ligands: current state and future perspectives in human lung cancer","volume":"1","author":"Han","year":"2010","journal-title":"World J. Biol. Chem."},{"key":"10.1016\/j.ejps.2018.08.019_bb0065","doi-asserted-by":"crossref","first-page":"11537","DOI":"10.3390\/molecules180911537","article-title":"Analysis of biotinylated generation 4 poly(amidoamine) (PAMAM) dendrimer distribution in the rat brain and toxicity in a cellular model of the blood-brain barrier","volume":"18","author":"Hemmer","year":"2013","journal-title":"Molecules"},{"key":"10.1016\/j.ejps.2018.08.019_bb0070","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/1523-1747.ep12340708","article-title":"Role of p53 in UVB-induced apoptosis in human HaCaT keratinocytes","volume":"109","author":"Henseleit","year":"1997","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.ejps.2018.08.019_bb0075","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.canlet.2011.01.012","article-title":"Targeting apoptosis pathways by celecoxib in cancer","volume":"332","author":"Jendrossek","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejps.2018.08.019_bb0080","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1158\/1541-7786.MCR-14-0397-T","article-title":"Targeted deletion and lipidomic analysis identify epithelial cell COX-2 as a major driver of chemically induced skin cancer","volume":"12","author":"Jiao","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ejps.2018.08.019_bb0085","first-page":"4926","article-title":"Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398","volume":"60","author":"Joki","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2018.08.019_bb0090","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3109\/10520295.2012.724713","article-title":"Selective COX-2 inhibitor (celecoxib) decreases cellular growth in prostate cancer cell lines independent of p53","volume":"88","author":"Katkoori","year":"2013","journal-title":"Biotech. Histochem."},{"key":"10.1016\/j.ejps.2018.08.019_bb0095","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s11051-016-3423-0","article-title":"A review on comparative study of PPI and PAMAM dendrimers","volume":"18","author":"Kaur","year":"2016","journal-title":"J. Nanopart. Res."},{"key":"10.1016\/j.ejps.2018.08.019_bb0100","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4103\/0975-7406.142963","article-title":"Effect of methotrexate conjugated PAMAM dendrimers on the viability of MES-SA uterine cancer cells","volume":"6","author":"Khatri","year":"2014","journal-title":"J. Pharm. Bioallied Sci."},{"key":"10.1016\/j.ejps.2018.08.019_bb0105","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3892\/etm_00000040","article-title":"The use of Cox-2 and PPAR\u03b3 signaling in anti-cancer therapies","volume":"1","author":"Knopfov\u00e1","year":"2010","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.ejps.2018.08.019_bb0110","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/107327480200902S04","article-title":"Celecoxib: a specific COX-2 inhibitor with anticancer properties","volume":"9","author":"Koki","year":"2002","journal-title":"Cancer Control"},{"key":"10.1016\/j.ejps.2018.08.019_bb0115","first-page":"232","article-title":"Studies on intracellular trafficking of PAMAM dendrimer","volume":"1","author":"Lai","year":"2005","journal-title":"Nanotechnology"},{"key":"10.1016\/j.ejps.2018.08.019_bb0120","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/carcin\/14.5.833","article-title":"p53 mutations in human immortalized epithelial cell lines","volume":"14","author":"Lehman","year":"1993","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ejps.2018.08.019_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2011.12.018","article-title":"Effect of celecoxib on proliferation, collagen expression, ERK1\/2 and SMAD2\/3 phosphorylation in NIH\/3T3 fibroblasts","volume":"678","author":"Li","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejps.2018.08.019_bb0130","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12935-015-0260-7","article-title":"Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity","volume":"15","author":"Liu","year":"2015","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejps.2018.08.019_bb0135","first-page":"127","article-title":"Contr\u00f4le du m\u00e9tabolisme par des ligands de PPAR\u03b3","volume":"7","author":"Maudelonde","year":"2005","journal-title":"M\u00e9decineTh\u00e9rapeutique\/m\u00e9decine de la reproduction."},{"key":"10.1016\/j.ejps.2018.08.019_bb0140","first-page":"733","article-title":"Inhibition of cyclooxygenase-2 and activation of peroxisome proliferator-activated receptor-gamma synergistically induces apoptosis and inhibits growth of human breast cancer cells","volume":"11","author":"Michael","year":"2003","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ejps.2018.08.019_bb0145","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.drudis.2016.02.006","article-title":"Dendrimer technologies for brain tumor","volume":"21","author":"Mishra","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejps.2018.08.019_bb0150","first-page":"1387","article-title":"Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro","volume":"33","author":"Morisaki","year":"2013","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejps.2018.08.019_bb0155","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.tiv.2009.09.014","article-title":"In vitro mammalian cytotoxicological study of PAMAM dendrimers \u2013 towards quantitative structure activity relationship","volume":"24","author":"Mukherjee","year":"2010","journal-title":"Toxicol. in Vitro"},{"key":"10.1016\/j.ejps.2018.08.019_bb0160","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1158\/1078-0432.CCR-08-0958","article-title":"Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer","volume":"14","author":"Mustafa","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2018.08.019_bb0165","doi-asserted-by":"crossref","first-page":"10403","DOI":"10.1039\/C5CC03075G","article-title":"Recent development of biotin conjugation in biological imaging, sensing, and target delivery","volume":"51","author":"Ren","year":"2015","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejps.2018.08.019_bb0170","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/nprot.2008.75","article-title":"Neutral red uptake assay for the estimation of cell viability\/cytotoxicity","volume":"3","author":"Repetto","year":"2008","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejps.2018.08.019_bb0175","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S1097-2765(01)00353-7","article-title":"A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity","volume":"8","author":"Rocchi","year":"2001","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejps.2018.08.019_bb0180","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.bbalip.2007.02.003","article-title":"Safety issues and prospects for future generations of PPAR modulators","volume":"1771","author":"Rubenstrunk","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejps.2018.08.019_bb0185","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.jinorgbio.2004.07.009","article-title":"Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumors","volume":"98","author":"Russel-Jones","year":"2004","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.ejps.2018.08.019_bb0190","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/156720110791011828","article-title":"Dextran carrier macromolecule for colon specific delivery of celecoxib","volume":"7","author":"Shrivastava","year":"2010","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.ejps.2018.08.019_bb0195","doi-asserted-by":"crossref","first-page":"215158","DOI":"10.1155\/2010\/215158","article-title":"The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies","volume":"2010","author":"Sobolewski","year":"2010","journal-title":"Int. J. Cell. Biol."},{"key":"10.1016\/j.ejps.2018.08.019_bb0200","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.3390\/molecules22071092","article-title":"In vitro effect of 8-prenylnaringenin and naringenin on fibroblasts and glioblastoma cells-cellular accumulation and cytotoxicity","volume":"22","author":"Stompor","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.ejps.2018.08.019_bb0205","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.canlet.2008.10.023","article-title":"Inhibition of COX-2 and activation of peroxisome proliferator-activated receptor \u03b3 synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells","volume":"275","author":"Sun","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejps.2018.08.019_bb0210","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/jocd.12103","article-title":"Increase in cyclooxygenase-2 (COX-2) expression in keratinocytes and dermal fibroblasts in photoaged skin","volume":"13","author":"Surowiak","year":"2014","journal-title":"J. Cosmet. Dermatol."},{"key":"10.1016\/j.ejps.2018.08.019_bb0215","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1016\/S0040-4020(03)00430-7","article-title":"Structure control within poly(amidoamine) dendrimers: size, shape, and region-chemical mimicry of globular proteins","volume":"59","author":"Tomalia","year":"2003","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejps.2018.08.019_bb0220","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4103\/2231-4040.90879","article-title":"The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases","volume":"2","author":"Tyagi","year":"2011","journal-title":"J. Adv. Pharm. Technol. Res."},{"key":"10.1016\/j.ejps.2018.08.019_bb0225","first-page":"4707","article-title":"In vitro cytotoxicity of the ternary PAMAM G3-pyridoxal-biotin bioconjugate","volume":"8","author":"Uram","year":"2013","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ejps.2018.08.019_bb0230","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.2147\/IJN.S87307","article-title":"Different patterns of nuclear and mitochondrial penetration by the G3 PAMAM dendrimer and its biotin-pyridoxal bioconjugate BC-PAMAM in normal and cancer cells in vitro","volume":"10","author":"Uram","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ejps.2018.08.019_bb0235","doi-asserted-by":"crossref","first-page":"945275","DOI":"10.1155\/2008\/945275","article-title":"PPAR\u03b3 and agonists against cancer: rational design of complementation treatments","volume":"2008","author":"Veliceasa","year":"2008","journal-title":"PPAR Res."},{"key":"10.1016\/j.ejps.2018.08.019_bb0240","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fendo.2017.00031","article-title":"PPAR-\u03b3 agonists as antineoplastic agents in cancers with dysregulated IGF axis","volume":"8","author":"Vella","year":"2017","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.ejps.2018.08.019_bb0245","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1042\/CS20080195","article-title":"PPAR\u03b3 and its ligands: therapeutic implications in cardiovascular disease","volume":"116","author":"Villacorta","year":"2009","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.ejps.2018.08.019_bb0250","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/00004424-199712000-00005","article-title":"Targeting dendrimer-chelates to tumors and tumor cells expressing the high affinity folate receptor","volume":"32","author":"Wiener","year":"1997","journal-title":"Investig. Radiol."},{"key":"10.1016\/j.ejps.2018.08.019_bb0255","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1134\/S000629791308004X","article-title":"Targeted delivery of doxorubicin: drug delivery system based on PAMAM dendrimers","volume":"78","author":"Yabbarov","year":"2013","journal-title":"Biochem. Mosc."},{"key":"10.1016\/j.ejps.2018.08.019_bb0260","first-page":"2933","article-title":"Biotinylated poly(amido)amine (PAMAM) dendrimers as carriers for drug delivery to ovarian cancer cells in vitro","volume":"29","author":"Yellepeddi","year":"2009","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejps.2018.08.019_bb0265","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1007\/s11051-013-1897-6","article-title":"Poly(amido)amine (PAMAM) denrimer-cisplatin complexes for chemotherapy of cisplatin-resistant ovarian cancer cells","volume":"15","author":"Yellepeddi","year":"2013","journal-title":"J. Nanopart. Res."},{"key":"10.1016\/j.ejps.2018.08.019_bb0270","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-J\u00e4rvinen","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2018.08.019_bb0275","first-page":"394","article-title":"Pharmacological profile of celecoxib, a specific cyclooxygenase-2 inhibitor","volume":"55","author":"Yoshino","year":"2005","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.ejps.2018.08.019_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2004.06.014","article-title":"Cyclooxygenases in cancer: progress and perspective","volume":"215","author":"Zha","year":"2004","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejps.2018.08.019_bb0285","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1600-0714.2011.01066.x","article-title":"The expression and significance of MRP1, LRP, TOPOII\u03b2, and BCL2 in tongue squamous cell carcinoma","volume":"41","author":"Zhang","year":"2012","journal-title":"J. Oral Pathol. Med."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098718303841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098718303841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T05:21:08Z","timestamp":1571721668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098718303841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":57,"alternative-id":["S0928098718303841"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2018.08.019","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biotinylated PAMAM G3 dendrimer conjugated with celecoxib and\/or Fmoc-l-Leucine and its cytotoxicity for normal and cancer human cell lines","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2018.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}